IPO Premiums
IPO calendar
SBSHEELListed

Sheel Biotech Limited

Bookbuilding IPO · NSE

Price band
₹59 - ₹63
Lot size
2,000 shares
Issue amount
₹34.02 cr
Total subscription
16.05×
Current price₹61
Listing price ₹91
Watch live price ↗
Opens
30 Sept 2025
Closes
3 Oct 2025
Allotment
6 Oct 2025
Listing
8 Oct 2025

Offer at a glance

Issue overview

Issue size
54,00,000 shares
Face value
₹10 per share
Minimum investment
₹1,18,000
Fresh issue
₹34.02 cr
Offer for sale
₹0 cr
Registrar
Skyline Financial Services Private Limited
Listing exchange
NSE
Maximum investment
₹1,26,000
Issue type
Bookbuilding IPO
Shares before issue
1,49,52,550
Shares after issue
2,03,52,550

Lot sizes

CategoryLotsSharesAmount
RETAIL24,000₹2,52,000
sHNI36,000₹3,78,000
bHNI816,000₹10,08,000

Share reservation

Anchor28.22%
QIB19%
HNI14.33%
RETAIL33.41%
Market Maker5.04%

Subscription & GMP

Subscription by category

Total subscribed16.05×

Reported 3 Oct 2025

QIB19.73×
NIB26.29×
RETAIL9.57×
HNIs(10L+)32.16×
HNIs(2-10L)14.56×

GMP history

07.51526 Sept: ₹029 Sept: ₹030 Sept: ₹01 Oct: ₹23 Oct: ₹64 Oct: ₹65 Oct: ₹26 Oct: ₹87 Oct: ₹153 Nov: ₹1521 Nov: ₹15
26 Sept₹1521 Nov

Day-wise demand

30 Sept0.07×
1 Oct0.37×
2 Oct0.37×
3 Oct16.05×

Application-wise demand

CategoryReserved applicationsApplied applications
QIB018
NIB01,363
RETAIL4514,315
HNIs(10L +)86761
HNIs (2-10L)43602

Subscription demand

Amounts in ₹ crore. HNI subcategories are included in the NII total.

CategoryOfferedDemand
QIBs6.46127.54
FIIs037.43
Others090.1
RETAIL11.37108.74
HNIs 2+1.6323.66
HNIs 10+3.25104.55

Financial performance

Company financials

In Crores · Reported periods may include interim results.

Revenue & profitIn Crores
050100150Mar 2022 · Revenue: 71.07Mar 2022 · Profit after tax: 4.51Mar 2022Mar 2023 · Revenue: 80.19Mar 2023 · Profit after tax: 5.08Mar 2023Mar 2024 · Revenue: 92.55Mar 2024 · Profit after tax: 10.51Mar 2024Mar 2025 · Revenue: 102.27Mar 2025 · Profit after tax: 10.63Mar 2025
RevenueProfit after tax

Key performance indicators

MetricMar-25Mar-24Mar-23
EPS7.217.223.5
ROE13.5915.388.23
ROCE000
RONW13.5915.388.23
PRE IPO(PE)8.9600
POST IPO(PE)44.0700

Values and labels as reported in the issue data.

Peer comparison

CompanyP/E(X)CMP* (₹)Face value (₹)NAV/Share (₹)RONW(%)EPS (Basic) (₹)
Sheel Biotech LimitedNANA1056.8413.597.21
Jain Irrigation Systems Limited143.9751.83272.070.50.36
Vrundavan Plantation Limited14.24471044.637.393.3

Company information

Company profile

Sheel Biotech Limited, incorporated in November 1991, specializes in biotechnology, floriculture, greenhouses, and organic farming. The company produces high-quality, disease-free plants for fruits, vegetables, ornamentals, and field crops using tissue culture and hydroponics, and provides greenhouse manufacturing, farmer services, and training through FPOs. It also offers landscaping services to government and private clients and holds ISO certifications for quality, environment, and safety. Its R&D lab is recognized by India’s Department of Biotechnology and Department of Science and Technology. Sheel Biotech supports organic farming adoption, manages FPOs, implements turnkey horticultural projects with modern technologies, and conducts training programs for farmers and agripreneurs. As of September 30, 2024, it had 160 permanent employees.

Strengths

  • Biotechnology and Greenhouse Expertise: Skilled in tissue culture, organic farming, and modern horticultural technologies.
  • Wide Product and Service Range: Offers planting materials, turnkey greenhouse projects, organic certification, FPO support, and training.
  • Sustainability and Recognition: Follows eco-friendly practices and holds government-recognized R&D and international quality, safety, and environmental certifications.

Risk factors

  • Strict Precision in Tissue Culture: Lapses in sterilization, storage, or temperature control can lead to contamination and significant losses.
  • Dependence on Government Tenders: Revenue from organic farming heavily relies on winning tenders, making it vulnerable to policy or tender changes.
  • Operational Risks in Production: Small errors in tissue culture processes can disrupt the entire production cycle.

Promoters

Dr. Satya Narayan Chandak

Mr. Sanjay Chandak

Mr. Divye Chandak

Mrs. Mini Chadha

M/s Satya Narayan Chandak (HUF)

M/s Sanjay Chandak (HUF)

M/s Sumeet Chandak (HUF)

Registrar & documents

Lead manager

Narnolia Financial Services Limited

Registered office

8 Balaji Estates , 2nd Floor, Block-C, Guru Ravidas Marg Kalkaji South Delhi, New Delhi, 110019

+91 88511 - 8980

[email protected]Company website ↗

Understanding SHEEL IPO data

Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.